Iron Triangle Partners LP Has $35.03 Million Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Iron Triangle Partners LP trimmed its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 41.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,943,790 shares of the company’s stock after selling 1,356,395 shares during the period. Teva Pharmaceutical Industries comprises about 4.9% of Iron Triangle Partners LP’s portfolio, making the stock its 8th largest position. Iron Triangle Partners LP’s holdings in Teva Pharmaceutical Industries were worth $35,027,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in TEVA. Sequoia Financial Advisors LLC raised its stake in Teva Pharmaceutical Industries by 0.7% in the third quarter. Sequoia Financial Advisors LLC now owns 112,380 shares of the company’s stock worth $2,025,000 after buying an additional 805 shares in the last quarter. Smithfield Trust Co raised its position in shares of Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after acquiring an additional 980 shares in the last quarter. Signaturefd LLC lifted its stake in shares of Teva Pharmaceutical Industries by 16.9% during the 3rd quarter. Signaturefd LLC now owns 7,583 shares of the company’s stock worth $137,000 after purchasing an additional 1,094 shares during the last quarter. Bridgewater Associates LP boosted its position in Teva Pharmaceutical Industries by 5.2% during the third quarter. Bridgewater Associates LP now owns 23,222 shares of the company’s stock valued at $418,000 after purchasing an additional 1,144 shares in the last quarter. Finally, QRG Capital Management Inc. grew its stake in Teva Pharmaceutical Industries by 0.8% in the second quarter. QRG Capital Management Inc. now owns 144,938 shares of the company’s stock valued at $2,355,000 after purchasing an additional 1,191 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insider Buying and Selling

In related news, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at $744,034.48. This represents a 30.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $16.65 on Tuesday. The stock has a fifty day moving average price of $17.54 and a 200 day moving average price of $17.36. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries Limited has a 12-month low of $9.35 and a 12-month high of $19.31.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on TEVA shares. JPMorgan Chase & Co. upped their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. UBS Group increased their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Finally, Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.